title: Real-life versus package insert: a post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers.
abstract: There are various methods to collect adverse events (AEs) in clinical trials. The methods how AEs are collected in vaccine trials is of special interest: solicited reporting can lead to over-reporting events that have little or no biological relationship to the vaccine. We assessed the rate of AEs listed in the package insert for the virosomal hepatitis A vaccine Epaxal(®), comparing data collected by solicited or unsolicited self-reporting. In an open, multi-centre post-marketing study, 2675 healthy travellers received single doses of vaccine administered intramuscularly. AEs were recorded based on solicited and unsolicited questioning during a four-day period after vaccination. A total of 2541 questionnaires could be evaluated (95.0% return rate). Solicited self-reporting resulted in significantly higher (p<0.0001) rates of subjects with AEs than unsolicited reporting, both at baseline (18.9% solicited versus 2.1% unsolicited systemic AEs) and following immunization (29.6% versus 19.3% local AEs; 33.8% versus 18.2% systemic AEs). This could indicate that actual reporting rates of AEs with Epaxal(®) may be substantially lower than described in the package insert. The distribution of AEs differed significantly between the applied methods of collecting AEs. The most common AEs listed in the package insert were reported almost exclusively with solicited questioning. The reporting of local AEs was more likely than that of systemic AEs to be influenced by subjects' sex, age and study centre. Women reported higher rates of AEs than men. The results highlight the need for detailing the methods how vaccine tolerability was reported and assessed.
authors.affiliation: Medical Department, Swiss Tropical and Public Health Institute Basel, Switzerland. Christoph.Hatz@unibas.ch
authors.forename: Christoph
authors.initials: C
authors.lastname: Hatz
authors.forename: Bernhard
authors.initials: B
authors.lastname: Beck
authors.forename: Robert
authors.initials: R
authors.lastname: Steffen
authors.forename: Blaise
authors.initials: B
authors.lastname: Genton
authors.forename: Valérie
authors.initials: V
authors.lastname: d'Acremont
authors.forename: Louis
authors.initials: L
authors.lastname: Loutan
authors.forename: Katharina
authors.initials: K
authors.lastname: Hartmann
authors.forename: Christian
authors.initials: C
authors.lastname: Herzog
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology*; D005260:Female; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011356:Product Labeling; D011358:Product Surveillance, Postmarketing / Q000379:methods*; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D022362:Hepatitis A Vaccines; C530970:epaxal berna